Abstract A013: Clinical Value of Tumor Mutational Burden (TMB) for Neoadjuvant and Adjuvant Immune Checkpoint Inhibitor (ICI) in Early-Stage (I-III) Non-Small Cell Lung Cancer (NSCLC)
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Julia Quintanilha, Gerald Li, Ryon Graf, Amaya Gasco, Jerry Mitchell, Richard Huang
Institution: Foundation Medicine (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7093346003
Cites:
Cited by:
Related to: